DNTH
Dianthus Therapeutics, Inc. /DE/
NASDAQ · Healthcare · Biotechnology · US
$96.81
−4.26%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.94
- Revenue estimate
- $443.9K
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.90
- EPS estimate
- -$0.85
- Revenue actual
- $761.0K
- Revenue estimate
- $297.2K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -8.5%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $139
- PT range
- $122 – $158
- Analysts
- 6
6 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.85 | -$0.90 | Miss -6.35% | $761.0K |
| May 5, 2026 | -$1.17 | -$0.85 | Beat 27.35% | $463.0K |
| Mar 9, 2026 | -$1.01 | -$1.43 | Miss -42.17% | $284.0K |
| Nov 5, 2025 | -$0.86 | -$0.97 | Miss -12.79% | $396.0K |
| Aug 7, 2025 | -$0.86 | -$0.88 | Miss -2.33% | $193.0K |
| Mar 11, 2025 | -$0.85 | -$0.81 | Beat 4.71% | $1.3M |
| Nov 7, 2024 | -$0.59 | -$0.74 | Miss -25.42% | $2.2M |
| Aug 8, 2024 | -$0.50 | -$0.51 | Miss -2.00% | $1.9M |
| May 9, 2024 | -$0.43 | -$0.54 | Miss -25.58% | $874.0K |
| Mar 21, 2024 | -$1.11 | -$0.71 | Beat 36.04% | $457.0K |
| Nov 9, 2023 | -$0.51 | -$3.78 | Miss -641.18% | $924.0K |
| Aug 3, 2023 | -$0.19 | -$0.05 | Beat 73.68% | $969.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026